GO
Loading...

Pharmaceuticals

More

  • Merck, Vertex MK-0457 Trials Halted on Heart Risk Tuesday, 20 Nov 2007 | 9:01 PM ET

    Vertex Pharmaceuticals said Merck & Co halted enrollment on trials of their investigational leukemia drug MK-0457 due to a potential heart safety issue in one patient.

  • It didn't take long for Japan's Takeda Pharmaceuticals, which trades on the Tokyo exchange, to try to capitalize on the new safety warning for GlaxoSmithKline's diabetes drug Avandia. Last week the FDA slapped a so-called "Black Box"--the agency's most severe warning--on the Avandia label advising patients and doctors about the potential heart attack and stroke risk that's been the subject of so much controversy over the past several months.

  • If the writer's strike has you looking for alternatives to insomnia-fighting late-night TV shows, then Pfizer may have just what the doctor ordered. Tune into the company's web cast for investors and analysts at 11 p.m. Eastern Daylight Savings Time on Thursday, November 29th. If you don't believe me check out the press release on the Pfizer web site. The world's biggest drug company is taking its show on the road to Hong Kong.

  • For a Monday before the Thanksgiving holiday, this is turning into an extremely busy day on the biotech beat. Two of the stories actually broke on Sunday: Celgene buying Pharmion for nearly $3 billion and Genentech announcing a breakthrough in brain cancer. Then, before the opening bell this morning Onyx Pharmaceuticals and Bayer won the expected Food and Drug Administration approval of their drug Nexavar for liver cancer.

  • Pfizer to Buy Cooley at 167% Premium Friday, 16 Nov 2007 | 11:06 AM ET
    Pfizer

    Pfizer, the world's biggest drugmaker, said Friday it has agreed to acquire Coley Pharmaceutical Group -- a developer of vaccine technology and drugs to treat cancer, asthma and other disorders -- for $164 million.

  • ImClone's Erbitux And The Passing Of Dr. Scott Hitt Friday, 16 Nov 2007 | 10:40 AM ET

    Last night, Bristol-Myers Squibb and ImClone Systems announced that a study being published in the prestigious "New England Journal of Medicine" shows their cancer drug Erbitux extended the lives of some metastatic colon cancer patients. The median survival of the people on Erbitux was just over six months versus about four-and-a-half months for those who got conventional drug treatment.

  • AstraZeneca Gets New US Approval for Seroquel XR Friday, 16 Nov 2007 | 8:58 AM ET

    AstraZeneca said on Friday that U.S. health regulators had approved Seroquel XR, an extended-release version of one of its top-selling drugs, as a maintenance treatment for adult schizophrenia patients.

  • J&J to Focus Beyond Traditional Lines of Business Thursday, 15 Nov 2007 | 1:16 PM ET
    Johnson & Johnson

    Health care products maker Johnson & Johnson, faced with lagging sales of some top products, said Thursday it would create three new units to boost prospects.

  • Buy Wyeth? Tuesday, 13 Nov 2007 | 10:39 AM ET

    What's the best reason to own a pharma stock right now? Consistency in the face of recession.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • State of the Market Tuesday, 13 Nov 2007 | 10:34 AM ET

    Stay in the game, Cramer says, but play it cautious.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Roche Says Avastin Study Misses Endpoint Tuesday, 13 Nov 2007 | 5:54 AM ET

    Roche on Tuesday said a late-stage study of its cancer drug Avastin in combination with gemcitabine chemotherapy and Tarceva for pancreatic cancer did not meet the primary endpoint for survival.

  • The surprising Vioxx settlement brought me back to the office today in the middle of my vacation--I could've literally phoned it in as I did on "Squawk Box" this morning, but as long as I was in town, I'm too hard core to stay at home working around the house when a big story like this one breaks on my beat.

  • Warnings Strengthened for Amgen, J&J Anemia Drugs Thursday, 8 Nov 2007 | 1:50 PM ET

    The warning labels have been strengthened on anemia drugs made by Amgen Inc and Johnson & Johnson to reflect concerns they may increase the risk of heart attacks, stroke and death, the companies and U.S. regulators said on Thursday.

  • Germany's Bayer will cut 1,500 jobs at its plastics unit -- 10 percent of the division's workforce -- despite a higher-than-expected rise in group quarterly operating profit, it said on Tuesday.

  • Novartis Diabetes Drug Faces Further Delays Tuesday, 6 Nov 2007 | 3:44 AM ET
    Novartis

    Novartis has found safety problems in higher doses of its key Galvus diabetes drug and will revise prescribing recommendations before launching in Europe.

  • Bayer Suspends Trasylol For Now, Awaits Study Monday, 5 Nov 2007 | 11:13 AM ET

    Germany's Bayer has suspended temporarily the global marketing of its anti-bleeding drug Trasylol, which has been linked to a higher risk of death, pending final results of a Canadian study for the medicine.

  • As I begin my vacation, I wanted to tell you about a story I did that's airing while I'm away on the new edition of CNBC's "Business Nation" this Wednesday (November 7th) at 9 p and midnight ET. It's about the increasingly strained relationship between drug sales reps and doctors.

  • Pharma Stocks To Watch On Monday (And My Time Off) Sunday, 4 Nov 2007 | 12:57 PM ET

    I'm taking some much needed time off for a couple of weeks. Actually, our scheduling guru at CNBC, Alex Crippen, told me if I don't use all of the days I've accumulated by the end of next month, I'll lose them. I consider myself a hard worker, but I'm not that generous. So, off I go.

  • Vertex In The "Vortex" Over Hepatitis C Test Results Friday, 2 Nov 2007 | 12:04 PM ET
    Vertex

    There's a flurry of selling going on this morning in shares of the biopharma Vertex Pharmaceuticals. Overnight the embargo lifted on the long awaited results of the company's mid-stage test on a new type of Hepatitis C drug. Two studies show that six months out 60% and 65% of patients had no detectable virus in their blood.

  • Zocor

    This morning we got more evidence about the havoc generic Zocor is wreaking on all of the companies that make brand-name statins--the pills to fight cholesterol. AstraZeneca is the latest casualty. On a down day in the markets AZN is one of the biggest losers in the sector.